NEW YORK, Sept 21 – The US National Cancer Institute (NCI) has purchased Nanogen’s (Nasdaq: NGEN) NanoChip system for use in cancer research and diagnosis, Nanogen said Thursday.
“The NanoChip system may accelerate this process, allowing us to potentially use this same tool in both the research process and in the patient care process,” Stephen Chanock of the NCI’s Pediatric Oncology Branch at the Advanced Technology Center said in a statement.
Terms of the deal were not disclosed. Representatives of NCI and Nanogen could not immediately be reached for comment.
Nanogen said they secured the sale only after the NCI tested the performance of several SNP-detection technologies for scoring the SNPs in the genes for Interleukin 4 and Interleukin 6 cytokines as well as the Interleukin 4 receptor. The sample included 48 patients.
The company recently began marketing its NanoChip Molecular Biology Workstation system to scientists and genomics laboratories for SNP scoring.
Other NanoChip customers include Aventis Research & Technologies, an affiliate of Aventis (NYSE: AVE), Egea BioSciences, and SKW Nature Products.
The company is also developing a series of electronics-based products to help researchers and clinical healthcare providers analyze DNA, RNA, and proteins.
Nanogen’s stock was up 15/16, or 4.8 percent, at 20 7/16 in late morning trading.